JP2019534277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534277A5 JP2019534277A5 JP2019520869A JP2019520869A JP2019534277A5 JP 2019534277 A5 JP2019534277 A5 JP 2019534277A5 JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019534277 A5 JP2019534277 A5 JP 2019534277A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- amino acid
- acid sequence
- sequence
- antibody construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162426A JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410054P | 2016-10-19 | 2016-10-19 | |
| US62/410,054 | 2016-10-19 | ||
| US201762549894P | 2017-08-24 | 2017-08-24 | |
| US62/549,894 | 2017-08-24 | ||
| US201762555498P | 2017-09-07 | 2017-09-07 | |
| US62/555,498 | 2017-09-07 | ||
| PCT/US2017/057268 WO2018075692A2 (en) | 2016-10-19 | 2017-10-18 | Antibody constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162426A Division JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534277A JP2019534277A (ja) | 2019-11-28 |
| JP2019534277A5 true JP2019534277A5 (enExample) | 2020-11-26 |
| JP7261158B2 JP7261158B2 (ja) | 2023-04-19 |
Family
ID=60452719
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520869A Active JP7261158B2 (ja) | 2016-10-19 | 2017-10-18 | 抗体構築物 |
| JP2022162426A Active JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162426A Active JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20180118811A1 (enExample) |
| EP (2) | EP3529269B1 (enExample) |
| JP (2) | JP7261158B2 (enExample) |
| KR (3) | KR20240000650A (enExample) |
| CN (3) | CN110177805B (enExample) |
| AU (1) | AU2017345454B2 (enExample) |
| CA (1) | CA3041254A1 (enExample) |
| DK (1) | DK3529269T3 (enExample) |
| ES (1) | ES3063689T3 (enExample) |
| FI (1) | FI3529269T3 (enExample) |
| IL (2) | IL326918A (enExample) |
| LT (1) | LT3529269T (enExample) |
| MX (1) | MX421186B (enExample) |
| PL (1) | PL3529269T3 (enExample) |
| PT (1) | PT3529269T (enExample) |
| WO (1) | WO2018075692A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| DK3529269T3 (da) * | 2016-10-19 | 2026-02-23 | Invenra Inc | Antistof-konstruktioner |
| WO2019183406A1 (en) * | 2018-03-21 | 2019-09-26 | Invenra Inc. | Multispecific antibody purification with ch1 resin |
| CA3094318A1 (en) | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
| WO2019204522A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Binding molecules |
| KR102999339B1 (ko) | 2018-04-18 | 2026-07-31 | 엑셀리시스, 인코포레이티드 | 항-ror 항체 구조체 |
| US20210380700A1 (en) * | 2018-07-06 | 2021-12-09 | Abmax Biopharmaceuticals | De-adcc/cdc functions of antibodies and their applications |
| EP3830129A4 (en) * | 2018-07-30 | 2022-05-04 | Invenra, Inc. | MULTISPECIFIC TREG BINDING MOLECULES |
| EP3864051A4 (en) * | 2018-10-10 | 2022-11-23 | Zymeworks Inc. | ANTIBODY CONSTRUCTS THAT BIND 4-1BB AND TUMOR-ASSOCIATED ANTIGENS AND THEIR USES |
| WO2020136566A1 (en) | 2018-12-24 | 2020-07-02 | Sanofi | Multispecific binding proteins with mutant fab domains |
| CA3171363A1 (en) * | 2019-12-20 | 2021-06-24 | Kisoji Biotechnology Inc. | Polypeptides, protein complexes and method for making same |
| MX2022010176A (es) * | 2020-02-20 | 2023-01-16 | Win Therapeutics Inc | Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso. |
| MX2023006899A (es) * | 2020-12-10 | 2023-09-04 | Invenra Inc | Mutaciones ortogonales para heterodimerización. |
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| TW202506726A (zh) * | 2023-04-07 | 2025-02-16 | 美商麥迪紐有限責任公司 | 雙特異性工程化抗體 |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8905551D0 (en) * | 1989-03-10 | 1989-04-19 | Unilever Plc | Detergent compositions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US20080305044A1 (en) | 2004-11-29 | 2008-12-11 | Seattle Genetics, Inc. | Engineered Antibodies and Immunoconjugates |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| KR20080080482A (ko) | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| AR074584A1 (es) | 2008-12-10 | 2011-01-26 | Mersana Therapeutics Inc | Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables |
| JP2012528240A (ja) | 2009-05-28 | 2012-11-12 | メルサナ セラピューティックス， インコーポレイテッド | 可変速度放出リンカーを含むポリアル−薬物コンジュゲート |
| JP5784592B2 (ja) | 2009-06-03 | 2015-09-24 | イミュノジェン・インコーポレーテッド | 抱合方法 |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| TWI603739B (zh) | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物 |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US8945865B2 (en) | 2011-03-10 | 2015-02-03 | Eisai R&D Management Co., Ltd. | Method for screening for compound capable of enhancing or inhibiting OATP1B1 transport activity, and method for determining expression level of OATP1B1 |
| EP2717916B1 (en) | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013033008A2 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| CN104822656B (zh) | 2012-05-15 | 2018-05-01 | 西雅图基因公司 | 自稳定接头偶联物 |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| WO2014008375A1 (en) | 2012-07-05 | 2014-01-09 | Mersana Therapeutics, Inc. | Terminally modified polymers and conjugates thereof |
| US20150239970A1 (en) | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| WO2014160360A1 (en) | 2013-03-14 | 2014-10-02 | Mersana Therapeutics Inc. | Tubulysin compounds and conjugates thereof |
| WO2015054659A1 (en) | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| CN105813653B (zh) | 2013-12-19 | 2020-06-26 | 西雅图基因公司 | 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物 |
| EP3107557B1 (en) | 2014-02-17 | 2021-06-09 | Seagen Inc. | Hydrophilic antibody-drug conjugates |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| CA2942150A1 (en) | 2014-04-07 | 2015-10-15 | Seattle Genetics, Inc. | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
| US9808528B2 (en) | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| TWI551060B (zh) * | 2014-09-24 | 2016-09-21 | 衡宇科技股份有限公司 | Ｂｃｈ解碼方法及其解碼器 |
| ES2935274T3 (es) * | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | Anticuerpo con intercambio de dominios |
| WO2016180941A1 (en) | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
| EP3778602B1 (en) | 2015-07-21 | 2023-07-12 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| GB2544086B (en) | 2015-11-05 | 2021-04-28 | Povey David | Drip catcher for a stemmed drinking vessel |
| TW201731532A (zh) | 2016-02-05 | 2017-09-16 | 伊繆諾金公司 | 用於製備細胞結合劑-細胞毒性劑結合物之有效方法 |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF |
| EP3241531A1 (en) * | 2016-05-04 | 2017-11-08 | noonee AG | Leg unit for a wearable sitting posture assisting device |
| DK3529269T3 (da) * | 2016-10-19 | 2026-02-23 | Invenra Inc | Antistof-konstruktioner |
| CN112384243A (zh) * | 2018-04-17 | 2021-02-19 | 英温拉公司 | 三价三特异性抗体构建体 |
| WO2019204522A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Binding molecules |
| KR102999339B1 (ko) * | 2018-04-18 | 2026-07-31 | 엑셀리시스, 인코포레이티드 | 항-ror 항체 구조체 |
| EP3830129A4 (en) * | 2018-07-30 | 2022-05-04 | Invenra, Inc. | MULTISPECIFIC TREG BINDING MOLECULES |
| WO2021145946A1 (en) * | 2020-01-13 | 2021-07-22 | Invenra Inc. | Multispecific treg binding molecules |
-
2017
- 2017-10-18 DK DK17804323.8T patent/DK3529269T3/da active
- 2017-10-18 CN CN201780078920.7A patent/CN110177805B/zh active Active
- 2017-10-18 EP EP17804323.8A patent/EP3529269B1/en active Active
- 2017-10-18 CA CA3041254A patent/CA3041254A1/en active Pending
- 2017-10-18 ES ES17804323T patent/ES3063689T3/es active Active
- 2017-10-18 KR KR1020237043908A patent/KR20240000650A/ko active Pending
- 2017-10-18 JP JP2019520869A patent/JP7261158B2/ja active Active
- 2017-10-18 EP EP25218239.9A patent/EP4729535A3/en active Pending
- 2017-10-18 PT PT178043238T patent/PT3529269T/pt unknown
- 2017-10-18 MX MX2019004690A patent/MX421186B/es unknown
- 2017-10-18 KR KR1020257008855A patent/KR20250044934A/ko active Pending
- 2017-10-18 US US15/787,640 patent/US20180118811A1/en not_active Abandoned
- 2017-10-18 LT LTEPPCT/US2017/057268T patent/LT3529269T/lt unknown
- 2017-10-18 IL IL326918A patent/IL326918A/en unknown
- 2017-10-18 FI FIEP17804323.8T patent/FI3529269T3/fi active
- 2017-10-18 CN CN202410343134.7A patent/CN118359705A/zh active Pending
- 2017-10-18 PL PL17804323.8T patent/PL3529269T3/pl unknown
- 2017-10-18 KR KR1020197013738A patent/KR102617264B1/ko active Active
- 2017-10-18 WO PCT/US2017/057268 patent/WO2018075692A2/en not_active Ceased
- 2017-10-18 AU AU2017345454A patent/AU2017345454B2/en active Active
- 2017-10-18 CN CN202410332902.9A patent/CN118359704A/zh active Pending
-
2019
- 2019-04-18 IL IL266143A patent/IL266143B2/en unknown
-
2022
- 2022-10-07 JP JP2022162426A patent/JP7591015B2/ja active Active
- 2022-11-15 US US18/055,720 patent/US20240043502A1/en not_active Abandoned
-
2025
- 2025-07-21 US US19/275,881 patent/US20260184765A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521781A5 (enExample) | ||
| FI3529269T3 (fi) | Vasta-ainerakenteita | |
| JP2021522162A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| IL274071B1 (en) | Method for in vivo generation of multispecific antibodies from monospecific antibodies | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021530251A5 (enExample) | ||
| JP2023085476A5 (enExample) | ||
| JP2022512234A5 (enExample) | ||
| JP2024167313A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| JP2022507487A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2020519643A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2017534644A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| RU2015129762A (ru) | ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2017528117A5 (enExample) | ||
| FI3392276T3 (fi) | Heterodimeerimolekyyli, joka perustuu rakenteelliseen CH3-domeeniin, sekä menetelmä sen valmistamiseksi ja sen käyttö | |
| JP2017529067A5 (enExample) | ||
| JP2017533694A5 (enExample) | ||
| JP2015146822A5 (enExample) | ||
| JP2013545455A5 (enExample) |